REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1

Q1 2022 13F Holders as of 31 Mar 2022

Type / Class
Debt / NOTE 1.750% 2/1
Unit price / market price
$0.9406
Total 13F principal
$249,383,000
Principal change
-$19,029,187
Total reported value
$239,572,000
Number of holders
19
Value change
-$21,994,040
Number of buys
5
Number of sells
6

Institutional Holders of REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 as of Q1 2022

As of 31 Mar 2022 REVANCE THERAPEUTICS INC - NOTE 1.750% 2/1 had 19 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions held a total of $249,383,000 principal (par value or face value) of the bond of the company.
Largest 10 bondholders included Antara Capital LP, FRANKLIN RESOURCES INC, LAZARD ASSET MANAGEMENT LLC, Kohlberg Kravis Roberts & Co. L.P., CITADEL ADVISORS LLC, ZAZOVE ASSOCIATES LLC, CAPSTONE INVESTMENT ADVISORS, LLC, AVIVA PLC, AMUNDI, and LMR Partners LLP.
This table shows 19 bond principal holders of the security as of 31 Mar 2022.
Investor Option Weight % Change % Value $ * Price $ Principal Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.